Vaccines in the treatment of invasive candidiasis

Xiao-juan Wang1,2,†, Xue Sui1,3,†, Lan Yan1,*, Yan Wang1, Yong-bing Cao1, and Yuan-ying Jiang1,*

† These authors contributed equally to this work.

Keywords: Candida albicans, immune response, invasive candidiasis, vaccine, virulence

Candida albicans is the most common cause of hematogenously disseminated candidiasis, and this disease is particularly prevalent in immunocompromised patients. The mortality of invasive candidiasis remains 40% to 50% even with the proper treatment with current antifungal drugs. Recently, with the better understanding of host-fungus interactions, notable progress has been made in antifungal vaccine research. Most antifungal vaccines exert protection by inducing either (or both) B-cell and T-cell responses. Here we summarize the current available information on C. albicans vaccines, highlight the obstacles that researchers identified, and offer several suggestions.

Introduction

Invasive candidiasis is the third to fourth most common bloodstream infection in the United States. The mortality of invasive candidiasis is 40% to 50%, even with proper antifungal therapies. In China, the incidence (from 4.12% to 41.18%) and mortality (from 9.8% to 60.0%) of opportunistic invasive fungal infections are somewhat different. Overall Candida albicans is the most common Candida species causing candidemia, followed by Candida glabrata, Candida parapsilosis, Candida tropicalis, and Candida krusei. C. albicans is fundamentally a human commensal and its interaction with the host immune system plays an important role in both commensalism and infection. Systemic candidiasis occurs predominantly as a consequence of some high-risk medical procedures like central venous catheters, immunosuppressive therapy, surgery, and exposure to broad spectrum antibiotics.

In recent years, a number of publications have confirmed the immunogenicity and efficacy of vaccines against candidiasis in animal models, and even have tested the efficacy and safety in clinical trials. Fungal cell-wall polysaccharide, proteins, and live attenuated fungi have been investigated as vaccine targets. Even considering the capital and technical barriers, bringing protective vaccines to the clinic appears promising. Here we summarize the latest candidate Candida vaccines and their protective mechanisms. We also offer possible approaches to strengthen vaccines’ triggering of the host immune response.

Live Attenuated C. albicans Strain

Saville et al. selected a genetically engineered C. albicans tet-NRG1 strain as an attenuated vaccine against disseminated candidiasis. In general, the morphogenetic transition between yeast and filamentous growth is one of the important virulence factors in C. albicans. NRG1 is a negative regulator of filamentation in C. albicans. In the tet-NRG1 strain, the expression level of NRG1 can be regulated by doxycycline (DOX) both in vitro and in vivo. Without the antibiotic, the high level of NRG1 blocks the yeast-to-hyphal transition, while DOX treatment inhibits the expression of NRG1 to allow hyphal formation. In the model, the C. albicans tet-NRG1 strain was grown overnight without DOX, then 1.7 × 10^6 cells in 200 µl saline were injected into female mice via the lateral tail vein. Two weeks later, all mice received 5.2 × 10^5 cells of a fully virulent C. albicans CAF-2 strain. The survival fraction was monitored during the following 16 d. The mice immunized with the tet-NRG1 strain were 100% viable compared to 100% mortality in the saline group. Furthermore, B-cell-deficient, T-cell-deficient, and neutropenic (DBA/2N) mice were used to evaluate the efficiency of the tet-NRG1 strain with the same vaccination approach. Both the B-cell-deficient and DBA/2N mice showed 100% survival versus 100% mortality in the control mice, while the vaccine failed to exert protection in the T-cell-deficient mice. According to these experiments, the protection of the attenuated tet-NRG1 strain relied on a T-cell-mediated adaptive immune response. In our laboratory, an attenuated C. albicans strain (CaLY55) has shown an exciting protective effect against disseminated candidiasis in mice (unpublished data). However, because of the complexity of their antigens, applying attenuated vaccines in the clinic will challenge the safety requirements of the FDA.

Protein Vaccines

Live attenuated C. albicans strains have complex antigens that have not been well characterized, leading to restrictions in their
application as vaccines. Thoroughly studied protein vaccine candidates such as Sap2p and Als3p are simple and have clearly defined amino acid sequences. Protein vaccines are potentially safer than the attenuated C. albicans strain and have a wider scope of application in patients.\textsuperscript{14,18,19}

**Sap2p**

The secreted aspartyl proteinase (SAP) family has at least 10 different members, designated Sap1p to Sap10p.\textsuperscript{20,21} Naglik et al.\textsuperscript{22} analyzed gene expression in over 130 subjects with oral and vaginal \textit{C. albicans} infections and found that SAP2 and SAP5 were the most common genes expressed. Other research\textsuperscript{23} reached a similar conclusion - that SAP2, SAP4–6 and SAP7 were the predominant proteinases expressed in patients both with vulvovaginal candidiasis (VVC) and recurrent vulvovaginal candidiasis (RVVC). In the candidal vaginitis model,\textsuperscript{24} rats were immunized with 100 \( \mu \)g SAP, in which Sap2p is the majority protein, via intravaginal (i.vag.) or intranasal (i.n.) routes, with or without cholera toxin (CT). SAP vaccination resulted in significant fungal clearance in vagina, and 3 weeks after the infection no fungus was detected in the vaccination group compared to the control. Both administration routes for SAP vaccination resulted in the similar protection, and induced protective IgA antibodies when added with CT.

Recently, research reported by Bernardis et al.\textsuperscript{25} demonstrated a protective Sap2 protein vaccine, PEV7. PEV7 is a truncated recombinant \textit{C. albicans} Sap2p consisting of amino acids 77 to 400 incorporated into the lipid bilayer of the influenza virosomes, and is designed to protect against RVVC. In the preclinical studies, IgG specific for Sap2p, was significantly induced in NMRI mice immunized with PEV7 via intramuscular (i.m.) injection compared to the control mice. In a rat model of candidal vaginitis, PEV7 generated adequate and persistent protection against \textit{C. albicans} after i.m. immunization whereas i.vag. resulted in a lower response. Furthermore, the PEV7-immunized rats had prolonged survival times and accelerated clearance of fungi. Most of all, PEV7 was also found to be safe in a repeated-dose toxicological study in rats. According to Edwards’s review article,\textsuperscript{14} a Sap2p vaccine is one of the more promising candidates and has gone through Phase I clinical trials against \textit{C. albicans} infection. This active vaccine, which is now in development by Pevion Biotech, prevents vaginitis caused by \textit{C. albicans} and shows both tolerability and efficacy in humans.

**Als1p and Als3p**

Agglutinin-like sequence (Als) proteins locate to the surface of \textit{C. albicans} and play important roles in the pathogen’s adhesion to human endothelial cells and in the development of invasive candidiasis.\textsuperscript{26–29} Edwards and his co-workers have explored several vaccines against invasive candidiasis, including rAls1p-N (recombinant N-terminus of Als1p),\textsuperscript{10,11,13} rAls3p-N (recombinant N-terminus of Als3p),\textsuperscript{31,32} and NDV-3 (recombinant N-terminus of Als3p formulated with alum adjuvant).\textsuperscript{13,15}

rAls1p-N (amino acids 17 to 432 of Als1p) was produced in \textit{Saccharomyces cerevisiae} by recombinant technology and purified by gel filtration and Ni-nitrilotriacetic acid matrix affinity purification. Mice were immunized with rAls1p-N and complete Freund’s adjuvant subcutaneously (s.c.) at day 0, then boosted with different dosage of rAls1p-N with incomplete Freund’s adjuvant at day 21. Two weeks after the boost, vaccinated mice and the control mice were infected with a lethal inoculum of \textit{C. albicans}.\textsuperscript{10} In the following 30 days, rAls1p-N vaccination improved the survival rate to 50%–57% compared to 100% lethality in the controls, and decreased significantly the fungal burden in the kidney. Meanwhile, mice immunized with the same dosage of rAls1p-N intraperitoneally (i.p.) resulted in 25% survival.\textsuperscript{30} These experiments remind us that vaccines should have a proper administration method. In particular, rAls1p-N vaccination still had significant protective effects in neutropenic mice, B-cell-deficient mice, and in murine models of oropharyngeal candidiasis and \textit{Candida} vaginitis. According to these experiments, the protective mechanism of rAls1p-N vaccination relied on T cells rather than B cells.

Als3p is involved in adherence, biofilm formation, and cell invasion.\textsuperscript{33,34} rAls3p-N (amino acids 17 to 432 of Als3p) vaccination induced a stronger antibody response than rAls1p-N and provided a similar cell-mediated protection efficacy when combating oropharyngeal or vaginal candidiasis.\textsuperscript{34} Mice were immunized with rAls3p-N in the same way as rAls1p-N. In the murine oropharyngeal candidiasis model, rAls3p-N vaccination significantly reduced the tongue fungal burden and inflammatory response. Similarly, in a model of \textit{Candida} vaginitis, rAls3p-N vaccination generated a remarkable reduction in vaginal fungal burden. In the mouse model of disseminated candidiasis, rAls3p-N vaccination notably improved the survival time. However, since the rAls3p-N-vaccinated mice that did not survive had high antibody titers, the antibody titers did not significantly correlate with a protection effect. Compared with rAls1p-N, rAls3p-N vaccination was more effective in treating oropharyngeal candidiasis.

To further clarify the protective mechanism of rAls3p-N, the authors conducted a series of experiments to explore the mechanism of rAls3p-N vaccine plus aluminum hydroxide (Al(OH)\textsubscript{3}) adjuvant in a mouse candidiasis model.\textsuperscript{32} IFN-\( \gamma \)-deficient mice immunized with CD4\textsuperscript{+} lymphocytes from the rAls3p-N-vaccinated wild type donor mice had approximately 40% survival, indicating that CD4\textsuperscript{+} lymphocyte-derived IFN-\( \gamma \) was important in combating \textit{C. albicans}. In cyclophosphamide-induced neutropenic or gp\textsuperscript{91phox/-} deficient mice (unable to generate superoxide and have impaired function in killing microbes), no protection was created by rAls3p-N vaccination, suggesting that neutrophils play an essential role in the protection. Moreover, in IL-17A-deficient mice, there was no vaccine-induced protection either when compared to the control mice. Then the vaccinated IL-17A-deficient mice and the vaccinated wild-type mice were cross-adoptively transferred CD4\textsuperscript{+} cells. As expected, the transfer of CD4\textsuperscript{+} cells from the wild type mice conferred higher protection than transfers from the IL-17A-deficient mice. According to these experiments, IL-17A derived from CD4\textsuperscript{+} lymphocytes was necessary for protection. In addition, the protective mechanism also involved many cytokines; for example,
the neutrophil activating chemokines KC and MIP-1α. In the rAls3p-N vaccinated mice, higher levels of Th1, Th17 and Th1/17 cells were detected than in the control mice.

Taken together, the rAls3p-N vaccine improved protection against C. albicans infection in mice by inducing Th1, Th17, and Th1/17 lymphocytes, thereby produced cytokines and the recruitment of neutrophils to the infection sites. IL-17A was not necessary for defense against C. albicans challenge in non-vaccine immune defense, but was necessary in vaccine-induced protection.

rAls3p-N formulated with alum adjuvant (NDV-3) has been tested in a Phase I clinical trial, and has shown to be well tolerated even at 300 mg.55 The majority of the subjects had a robust humoral immune response, and elicited high titres of antibody within 3–7 d of administration. As well, the production of IFN-γ and IL-17A was increased. These observations suggest that in humans, NDV-3 stimulated T cells, B cells and antibody responses.

**Hsp90p**

Heat shock protein 90 (Hsp90), a stress-induced cellular chaperone, is highly conserved within Candida species.35,36 An Hsp90 DNA vaccine (1 μg) was tested with 2 administration methods, i.m. and intradermal (i.d.) injection.37 Mice vaccinated with a DNA vaccine via i.d. resulted in 64% prolonged survival times compared to a PBS control, whereas vaccination via i.m. did not lead to protection. As well, recombinant protein r-hsp90-CA resulted in a 118% increase in survival compared with the PBS control group. Moreover, Mycograb® (Neu Tec Pharma) is a monoclonal antibody binds to the immunodominant epitope of C. albicans Hsp90p. Mycograb consists of the variable ends of the heavy and light chains which were linked together by 2 cross-cysteine bonds.38 In preclinical studies, results from checkerboard methods demonstrated the synergistic action of Mycograb with amphotericin B (AMB) against both fluconazole-sensitive and fluconazole-resistant C. albicans strains. In a mouse model of systemic candidiasis, 2 mg/kg of Mycograb in combination with AMB improved the killing of Candida compared with AMB treatment alone.39 In a multicenter double blind placebo-controlled trial of patients with invasive candidiasis, complete mycological resolution reached 84% in the combination therapy group compared to 48% in the AMB monotherapy group. Moreover, the clearance of infections in the combination therapy group was twice that for the AMB therapy alone, resulting in mortality of 18% compared to 4%. Although the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion because of both quality and safety concerns, monoclonal antibodies in the treatment of invasive candidiasis is still a promising approach.38

**Hyr1p**

Hyr1p is a glycosyl phosphatidylinositol (GPI)–anchor mannanprotein on the cell wall of C. albicans40,41 and enhances C. albicans resistance to neutrophil killing.42 rHyr1p-N (amino acids 25–350 of Hyr1p) was produced in an Escherichia coli pQE-32 expression system, and purified by a 6 x His tag.42 Mice were immunized with 20 μg rHyr1p-N in complete Freund’s adjuvant via subcutaneous injection and boosted on day 21 with incomplete Freund’s adjuvant. Fourteen days after the boost, mice were infected with 2.2 × 10⁷ cells of C. albicans SC5314. Meanwhile, alum was also evaluated as an adjuvant in vaccine protection. Mice were immunized with 33 μg rHyr1p-N in 0.1% alhydrogel and then infected with 7 × 10⁷ cells of C. albicans strain 15563. The results showed that vaccination with rHyr1p-N mixed with adjuvant markedly improved survival to 60% or 70%. However, so far there has been no specific information available about its behavior in preclinical studies.

**Cell wall extract**

In Thomas’s study,43 mice were vaccinated subcutaneously with cell wall proteins obtained through β-mercaptoethanol (β-ME) extraction of C. albicans. In the immunization group, the β-ME extract (40 μg) was injected subcutaneously combined with Ribi Adjuvant System (RAS) R-700. After 3 weeks, mice in the vaccinated group received a booster injection in the same way. Eight days after the booster injection, each mouse received 1 × 10⁶ C. albicans cells via intravenous injection. Some mice were sacrificed on day 3 after injection, and kidneys and blood were collected to further evaluate the vaccine. The remaining mice were monitored for survival. 75% of the vaccinated mice survived during the 28 day observation period while the unvaccinated mice all died. The results of colony formation units (CFUs) and histopathological analysis (GMS staining) in the kidneys showed that the C. albicans β-ME extract significantly decreased the tissue fungal burden and inflammatory lesions when compared to the control mice. According to the ELISA test of the anti-sera, vaccination elicited both high IgG and IgM responses. Two-DE and mass spectra were further used to identify a total of 20 unique antigenic proteins in β-ME extract, among which Mp58/Pra1p is the most abundant protein. As well, the β-ME extract also included glycolytic enzymes and heat shock proteins. In such cases, proteomic techniques can identify the diversity of proteins present in vaccines derived from cell wall extracts.

**Glycoconjugates Vaccines**

The combination of polysaccharide with protein, in which the polysaccharide acts as a carrier, could elicit T cell response and have the potential to directly inhibit fungal growth. This approach can broaden the spectrum of protection and decrease the chances of immune evasion.18,44-50

**β-Mannan and peptide conjugates**

An innovative β-mannan vaccine has been generated by Xin et al.51 The glycopeptide vaccines were created by combining β-mannan and peptide epitopes. The linker was a non-immunogenic, cross-coupling reagent, which resulted in a stable amide bond. Six T-cell peptides found in C. albicans cell wall proteins were selected by algorithm peptide epitope searches; each was synthesized and conjugated to the fungal cell wall.
β-mannan trisaccharide [β-(Man)$_3$] by a novel saccharide-peptide linker chemistry to create glycopeptide conjugates. The vaccination of β-(Man)$_3$-Fba, β-(Man)$_3$-Met6 or β-(Man)$_3$-Hwp1 each induced significant protection against experimental disseminated candidiasis in mice, and reduced kidney fungal burden, while the vaccination of the β-(Man)$_3$-Eno1 or β-(Man)$_3$-Gap1 gave moderate protection, and the β-(Man)$_3$-Pbk1 conjugate slightly enhanced candidiasis. The immunized groups that received the β-(Man)$_3$-Hwp1, β-(Man)$_3$-Fba, or β-(Man)$_3$-Met6 conjugates showed 80–100% survival throughout the 120 day post-challenge observation period. This original approach employing fully chemically synthetic and defined immunogens has widespread implications for the development of vaccines. Recently, Xin et al. have shown that a peptide alone (Fba) is highly protective as an active vaccine against several C. albicans strains.

**β-Glucan conjugate vaccine**

β-glucan conjugated with the MF59 adjuvant, which has been used extensively in influenza vaccines in Europe, but is not approved by the FDA for use in the United States, showed excellent protection in the murine vaginal candidiasis model. This protection was due to the anti-β-glucan IgG in serum and in the vagina. Another glucan vaccine is β-glucan-CRM197 which is a laminarin-diphtheria toxoid (CRM197) conjugate vaccine Lam-CRM197. When Lam-CRM197 was administered with MF59, the mortality of the infected mice decreased. Passive transfer experiments demonstrated that the protection in an invasive candidiasis model derived through such vaccination was mediated by antibodies.

**Attempted Approaches to Strengthen Vaccines’ Immune Response Stimulation**

As mentioned above, we know that current C. albicans vaccines play important roles in the prevention of candidiasis, which are primarily due to their reinforcement of immunogenicity. Here, we give some suggestions for the production of the ideal vaccine that can elicit strong immune response.

**Target selection**

Fungal cell walls are indispensable organelles and are composed of molecules that are largely absent in mammals. The cell wall plays an important role in continuing cell wall biosynthesis, in growth, in budding in C. albicans and especially in crucial host-fungus interactions that facilitate the establishment of human mycoses. Most virulence factors, including those involved in adhesion, invasion, and the yeast-to-hypha transition, localize at the cell wall, and include proteins such as Hsp90p, Sap2p, Als1p and Als3p. Thus cell wall proteins might be ideal vaccine targets for inducing a protective immune response in the host.

**Glycosylation of the vaccine**

Since recombinant proteins have been generally produced in E. coli, the expressed proteins aren’t glycosylated as they would be in eukaryotic cells, with the result that they differ from the natural structure. Although non-glycosylated proteins are able to mediate protective immunity, glycoconjugates (mannans and β-glucans) have been tested to establish whether it is necessary to be glycosylated to enhance immune response. Specht et al. have established the role of mannosylation in inducing protection with protein vaccines against Cryptococcus by comparing the protective efficacy of the mannosylated and unmannosylated recombinant proteins produced separately by Pichia pastoris and E. coli. Both recombinant proteins generate immune protection against Cryptococcus infection. However, the mannosylated protein has the additional ability to induce a potent T cell-mediated immune response, and to protect against infection. Moreover, yeast-mannosylated ovalbumin induced greater T cell proliferation than unmannosylated ovalbumin produced in E. coli; this effect was attributed to O-mannosylation rather than N-mannosylation. Mannosylation enhanced both CD8$^+$ T cell proliferation, and the secretion of proinflammatory cytokines, such as tumor necrosis factor (TNF) and IL-12. However, in the case of chemical deglycosylation, the mannosylated protein would turn into unmannosylated protein, leading to the disappearance of the above effects of mannosylation. Hence, most attention should be directed at the study of the vaccines with polysaccharides or glycoconjugates against C. albicans, which are based on β-mannan, β-glucan and their oligosaccharide synthesis.

**Suitable adjuvants**

The majority of immune response enhancement methods are based on the vaccine itself in the design and production stages. However, the adjuvant is also a key factor in enhancing the immune response by promoting the antigenicity of an immunogen. It causes substantial and additional activation of T-cells or B-cells. In recent years, Freund’s adjuvant has been extensively used in animals, especially in mice models. But now it’s no longer recommended because of its painful reaction and potential tissue damage. Instead, the alum adjuvant is widely used in humans. In the future, in order to achieve better efficacy without side effects, new adjuvants or modified adjuvants should be tested.

**Delivery by dendritic cells**

Dendritic cells (DCs) are antigen-presenting cells that have a branching or dendritic morphology and have phagocytic functions; DCs connect innate immunity with adaptive immunity. Using DCs as vehicles to present vaccines to T cells would promote the proliferation of specific antigens and the cell-mediated immune response. The localization of DC vaccination is different depending on the injection process. Intravenous injection leads to DC localization in the reticuloendothelial system and the lungs, whereas subcutaneous injection targets DCs to the lymphatic system. DCs delivery shows advantages in immunocompromised patients over others.

Apart from DCs delivery, there are some other carriers, including nasal delivery systems, lipid particle delivery systems, DNA delivery, and virosome delivery, which are all approaches to enhance the activity of C. albicans vaccines.
Combining univalent vaccines into a multivalent vaccine

At present, most *C. albicans* vaccines are univalent. Since *C. albicans* possess many kinds of virulence factors, and one vaccine is usually specific to a single factor, other virulence factors would compensate, allowing *C. albicans* to escape from the immune response. In contrast, a multivalent vaccine that contains more than one unrelated antigen will provide better protection by eliciting effective immune responses and protective antibodies, as well as reducing the incidence of fungal immune evasion. Cascone has proposed a constructive idea to combine 2 unrelated, major virulence-associated immunogens as a multivalent vaccine. The recombinant antigens Als3p and Sap2p, which are currently in clinical trials, would be the first combination to explore. Although there are several technical and financial difficulties, production of multivalent vaccines is still a promising way to overcome *C. albicans* infection.

Passive immunotherapy

A significant challenge to the development of effective vaccines will be to elicit immune responses in immunocompromised individuals who are most at risk for invasive fungal infections. In these vulnerable patients, the vaccine usually elicits a weak immune response or nothing, or even generates side effects. In this circumstance, passive immunotherapy could be considered, which would involve opsonisation, complement fixation, immune response and protective antibodies. At present, monoclonal antibody C7 (MAB C7), and Mycograft, are both successful cases. MAB C7 was produced by standard methods with splenocytes from BALB/c mice immunized with intraperitoneal injections of a *C. albicans* high-molecular-weight stress mannanprotein recognized by salivary secretory immunoglobulin A (sIgA). MAB C7 exhibited a potent antifungal effect through inhibiting both germination and the adhesion of *C. albicans* to Hep-2 monolayers and BECs, and through direct candidacidal activity. Further studies claim that mAb C7 binds to the N terminus of Als3p and functions through the blockage of the reductive iron uptake pathway in *C. albicans*. Mycograft, as mentioned in section 3.3, binds to *C. albicans* Hsp90p and shows synergistic fungicidal effect with AMB in patients with invasive candidiasis. Antibodies will offer good prospects in immunotherapy especially in immunocompromised individuals. Full assessment of the efficacy in prevention, treatment, prognosis and recurrence would be helpful to determine the best drug administration period.

Problems and Proposals

Many positive results have been achieved in the current development of vaccines. Nevertheless, there are still several problems for us to solve - the following are the crucial points: (1) The vaccines show marked protection in animal models, but could be less effective in human; (2) The protection of the vaccine is not persistent or high-grade; (3) The vaccine could cause unacceptable toxicity, which brings new troubles in treatment; (4) There is no prefect standardized manufacturing process; (5) The clinical trials need many volunteers, involve high costs and have a long cycle; (6) Vaccines have a common disadvantage with biologics, it is difficult to maintain stability during the production, transportation, and storage processes.

Further understanding of the mechanisms of the *C. albicans*-host interaction and identification of some new targets would be of considerable importance. Then, in the preclinical trials, researchers need to consider. Using different species of animals, including mice, rabbits and monkeys, to test the effectiveness of vaccines; (2) Because hosts have different physical status, we should simulate many animal models to evaluate the efficacy of vaccines. These infection models could include immune-normal animals, immune-deficient animals, and could involve variations in the symbiotic bacteria in cross-infection animals; (3) To ensure the susceptibility of *C. albicans* before experiment; (4) The dose of *C. albicans* should be controlled at the required smallest inocula to infect the majority of animals and produce the intended outcome of death or tissue infection; (5) Observe the dosage and delivery time of the vaccines to produce the greatest protection effect; (6) Distinguish various routes of *Candida* infection; (7) Test multiple parameters, such as tissue CFU and survival rates. When the vaccines come to clinical trials, researchers should determine the appropriate dosing regimen in real-time tracking feedback according to the tolerance, pharmacokinetics, therapeutic effect and safety. Meanwhile, both the efficacy of the vaccine alone and the synergy of the other antifungal drugs should also be examined.

In summary, the traditional antifungal chemotherapy against systemic *C. albicans* infections has met some limitations, such as the toxicity and emergence of resistance to the limited options of antifungal drugs. Vaccines can represent novel approaches against *C. albicans* infection. Although the currently available vaccines have demonstrated good protection, there still exist problems such as how to elicit immune responses in immunocompromised individuals. Thus there is still long way to go to finally achieve a vaccine applied in patients.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments

We thank Malcolm Whiteway (Concordia University) for critical reading of our manuscript. The authors would like to apologize to all researchers whose important works were unable to be cited because of space limitations.

Funding

L.Y. is supported by Natural Science Foundation of China (31000079, 81470158) and Translational Medicine project of the Second Military Medical University (2014-01). Y.J. is supported by China National 973 Program (2013CB531602) and Natural Science Foundation of China (81330083). Y.C is supported by Natural Science Foundation of China (81173100).
References

1. Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH. An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Dis 2012; 10: 971-27; PMID:22075904; http://dx.doi.org/10.1038/nrd3570.

2. Liao Y, Chen M, Hartmann T, Yang RY, Liao WQ. Epidemiology of opportunistic invasive fungal infections in China: review of literature. Chin Med J (Engl) 2013; 126:23324200.

3. Romani L. Immunity to fungal infections. Nat Rev Immunol 2004; 4:1-23; PMID:14661066.

4. Garcia-Vidal C, Viasus D, Carratala J. Pathogenesis of invasive candidiasis: a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against heterogeneously disseminated candidiasis. Clinic Vaccine Immunol 2009; 16:430-2; PMID:19144791; http://dx.doi.org/10.1128/CFI.00328-CVI.2008.

5. Cassone A. Development of vaccines for Candida albicans: fighting a skilled transformer. Nat Rev Microbiol 2013; 11:884-9; PMID:24232568; http://dx.doi.org/10.1038/nrmicro1350.

6. Spellberg BJ, Ibrahim AS, Avanesian V, Fu Y, Myers CL, Edwards JE Jr. The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p improves survival during systemic candidiasis. Cryptococcus neoformans infection in mice. PLoS Pathog 2009; 5: e1000703; PMID:20041174; http://dx.doi.org/10.1371/journal.ppat.1000703.

7. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baqir B, Fu Y, French SW, Edwards JE Jr., Spellberg B. Th1-7 Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009; 5: e1000703; PMID:20041174; http://dx.doi.org/10.1371/journal.ppat.1000703.

8. Zhao X, Oh SH, Cheng G, Green CB, Nuesaen JA, Yeater K, Long RP, Brown AJ, Hoyer LL. ALS3 and ALS5 represent a single locus that encodes a Candida albicans adhesin; functional comparisons between ALS3p and ALS1p. Microbiology 2004; 150:2415-28; PMID:15256583; http://dx.doi.org/10.1099/mic.0.26943-0.

9. Phan QT, Myers CL, Fu Y, Sheppard DG, Yeaman MR, Welch WH, Ibrahim AS, Edwards JE Jr., Filler SG. Als1p is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol 2007; 5:e64; PMID:17311474.

10. Raska M, Belokova J, Horynova M, Krupka M, Novotny J, Sebestova M, Wegl E. Systemic and mucosal immunization with Candida albicans hsp90 elicits hsp90-specific humoral and vaginal mucosal which is further enhanced during experimental vaginal candidiasis. Med Mycol 2008; 46:411-20; PMID:18680941; http://dx.doi.org/10.1080/13693780701885308.

11. Matthews RC, Burnie JP. Recombinant antibodies: a natural partner in combinatorial antifungal therapy. Vaccine 2004; 22:865-71; PMID:15040939; http://dx.doi.org/10.1016/j.vaccine.2003.11.032.

12. Raska M, Belokova J, Wadatua NR, Kalvova L, Ruzickova K, Sebestova M, Wegl E. Comparative study of protective effect of protein and DNA vaccines hsp90 in murine model of systemic candidiasis. Folia Microbiol (Praha) 2005; 50:77-82; PMID:15954327.

13. Bagli F, Cacci M, Martin M, Torni P, Paterazzo B, Sangiennetti M, Parietti B. Human monoclonal antibody-based therapy in the treatment of invasive candidiasis. Clin Dev Immunol 2013; 2013:403121; PMID:23887583; http://dx.doi.org/10.1155/2013/403121.

14. Matthews RC, Rigg G, Hodgers S, Carter T, Chapman C, Gregory C, Illidge C, Burnie J. Preclinical Assessment of the Efficacy of Mycograp, a Human Recombinant Antibody against Fungal HSP70. Anti-mycobacterial Agents Chemother. 2003; 47:2208-16; PMID:12824170; http://dx.doi.org/10.1128/AAC.47.7.2208-2216.2003.

15. Cassone A, Bromero C, Chiani P, Torezanucci A. Hyr1 protein and beta-glucan conjugates as anti-Candida vaccines. J Infect Dis 2010; 202:1930; PMID:20180372; http://dx.doi.org/10.1086/655741.

16. Bailey DA, Feldmann PJ, Bovey M, Gow NA, Brown AJ. The Candida albicans HTR1 gene, which is activated in response to hyphal development, belongs to a gene family encoding yeast cell wall proteins. J Bacteriol 1998; 170:5353-60; PMID:9888922.

17. Lin G, Ibrahim AS, Spellberg B, Nuesaen JA, Avanesian V, Fu Y, Lipke P, Ono H, Xu X, Farber JM, Yeaman MR, Welch WH, Ibrahim AS, Edwards JE Jr., Filler SG. Als1p is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol 2007; 5:e64; PMID:17311474.

18. Osorio MA, Bundle DR. Designing a new antifungal glycosconjugate vaccine. Chem Soc Rev 2013; 42:4327-34.
44. PMID:23232662; http://dx.doi.org/10.1039/c2cs35382b
45. Bystricky S, Paulovicova E, Machova E. Candida albicans mannan-protein conjugate as vaccine candidate. Immunol Lett 2003; 85:251-5; PMID:12663139; http://dx.doi.org/10.1016/S0165-2478(02)00241-9
46. Han Y, Rhew KY. Comparison of two Candida mannan vaccines: the role of complement in protection against disseminated candidiasis. Arch Pharm Res 2012; 35:2021-7; PMID:23212645; http://dx.doi.org/10.1007/s12272-012-1120-9
47. Luong M, Lam JS, Chen J, Levitz SM. Effects of fungal N- and O-linked mannosylation on the immunogenicity of model vaccines. Vaccine 2007; 25:4340-4; PMID:17412460; http://dx.doi.org/10.1016/j.vaccine.2007.03.027
48. Lipinski T, Fitieh A, St Pierre J, Ostergaard HL, Bundle DR, Tousert N. Enhanced immunogenicity of a tri-component mannan tetanus toxoid conjugate vaccine targeted to dendritic cells via Dectin-1 by incorporating beta-glucan. J Immunol 2013; 190:4116-28; PMID:23514738; http://dx.doi.org/10.4049/jimmunol.1202937
49. Xin H, Cartmell J, Bailey JJ, Dziadek S, Bundle DR, Cutler JE. Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis. PLoS One 2012; 7:e35106; PMID:2256337; http://dx.doi.org/10.1371/journal.pone.0035106
50. Lam JS, Mansour MK, Specht CA, Levitz SM. A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity. J Immunol 2005; 175:7496-503; PMID:16301657; http://dx.doi.org/10.4049/jimmunol.175.11.7496
51. Xin H, Dziadek S, Bundle DR, Cutler JE. Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis. Proc Natl Acad Sci U S A 2008; 105:13526-31; PMID:18725625; http://dx.doi.org/10.1073/pnas.0803195105
52. Xin H, Cutler JE. Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis. Clin Vaccine Immunol 2011; 18:1656-67; PMID:21832099; http://dx.doi.org/10.1128/CVI.05215-11
53. Pietrella D, Rachini A, Torosantucci A, Chiani P, Brown AJ, Biston F, Costantino P, Mosci P, d’Enfert C, Rappuoli R, et al. A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. Vaccine 2010; 28:1717-25; PMID:20038431; http://dx.doi.org/10.1016/j.vaccine.2009.12.021
54. Bromuro C, Romano M, Chiani P, Berri F, Tontini M, Prioretti D, Moro E, Torosantucci A, Costantino P, Rappuoli R, et al. Beta-glucan-CRM197 conjugates as candidates antifungal vaccines. Vaccine 2010; 28:2615-23; PMID:20096763; http://dx.doi.org/10.1016/j.vaccine.2010.01.012
55. Specht CA, Noong S, Dan JM, Lee CK, Levitz SM. Contribution of glycosylation to T cell responses stimulated by recombinant Cryptococcus neoformans mannanprotein. J Infect Dis 2007; 196:796-800; PMID:17674324; http://dx.doi.org/10.1086/520536
56. Eggert AA, Schreurs MW, Boerman OC, Oyen WJ, de Boer AJ, Punt CJ, Figdor CG, Adema GJ. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999; 59:3340-5; PMID:10416590
57. Bren S, Omaetxebarria MJ, Elguezabal N, Cabezas J, Moragas MD, Ponton J. Fungaloidal monoclonal antibody C7 binds to Candida albicans Als3. Infection and immunity 2007; 75:3680-2; PMID:17452471; http://dx.doi.org/10.1128/IAI.01840-06
58. Moragas MD, Omaetxebarria MJ, Elguezabal N, Sevilla MJ, Contri S, Polonelli L, Ponton J. A monoclonal antibody directed against a Candida albicans cell wall mannanprotein exerts three anti-C. albicans activities. Infection and immunity 2003; 71:5273-9; PMID:12933874; http://dx.doi.org/10.1128/IAI.71.9.5273-5279.2003